CU20160018A7 - PHARMACEUTICAL COMPOSITIONS OF COMPOUNDS THAT INHIBIT THE ACTIVITY OF TYROSINE KINASE AND ITS PREPARATION METHODS - Google Patents
PHARMACEUTICAL COMPOSITIONS OF COMPOUNDS THAT INHIBIT THE ACTIVITY OF TYROSINE KINASE AND ITS PREPARATION METHODSInfo
- Publication number
- CU20160018A7 CU20160018A7 CUP2016000018A CU20160018A CU20160018A7 CU 20160018 A7 CU20160018 A7 CU 20160018A7 CU P2016000018 A CUP2016000018 A CU P2016000018A CU 20160018 A CU20160018 A CU 20160018A CU 20160018 A7 CU20160018 A7 CU 20160018A7
- Authority
- CU
- Cuba
- Prior art keywords
- pharmaceutical compositions
- inhibit
- activity
- compounds
- tyrosine kinase
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- -1 for example Chemical class 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen composiciones farmacéuticas que comprenden un compuesto que tiene la fórmula: o una sal farmacéuticamente aceptable del mismo, o un hidrato del mismo, y por lo menos un polímero farmacéuticamente aceptable. La sal farmacéuticamente aceptable del compuesto de la fórmula I o un hidrato del mismo puede ser una sal mesilato, incluyendo, por ejemplo, una sal mono-mesilato o una sal bis-mesilato o un hidrato de las mismas. También se describen métodos para utilizar las composiciones farmacéuticas.Pharmaceutical compositions are described comprising a compound having the formula: or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and at least one pharmaceutically acceptable polymer. The pharmaceutically acceptable salt of the compound of the formula I or a hydrate thereof may be a mesylate salt, including, for example, a mono-mesylate salt or a bis-mesylate salt or a hydrate thereof. Methods for using pharmaceutical compositions are also described.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201313618660A | 2013-07-30 | 2013-07-30 | |
| PCT/US2014/048733 WO2015017460A1 (en) | 2013-07-30 | 2014-07-29 | Polymorph of syk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20160018A7 true CU20160018A7 (en) | 2016-11-29 |
Family
ID=56565036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2016000019A CU20160019A7 (en) | 2013-07-30 | 2016-02-01 | POLYMORPH OF INHIBITORS OF TIROSINA KINASA DEL BAZO (SYK), METHODS OF PREPRATION AND COMPOSITIONS |
| CUP2016000018A CU20160018A7 (en) | 2013-07-30 | 2016-02-01 | PHARMACEUTICAL COMPOSITIONS OF COMPOUNDS THAT INHIBIT THE ACTIVITY OF TYROSINE KINASE AND ITS PREPARATION METHODS |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2016000019A CU20160019A7 (en) | 2013-07-30 | 2016-02-01 | POLYMORPH OF INHIBITORS OF TIROSINA KINASA DEL BAZO (SYK), METHODS OF PREPRATION AND COMPOSITIONS |
Country Status (1)
| Country | Link |
|---|---|
| CU (2) | CU20160019A7 (en) |
-
2016
- 2016-02-01 CU CUP2016000019A patent/CU20160019A7/en unknown
- 2016-02-01 CU CUP2016000018A patent/CU20160018A7/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20160019A7 (en) | 2016-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016001480A (en) | Formulation of syk inhibitors. | |
| DOP2020000102A (en) | HELPFUL COMPOUNDS TO INHIBIT CDK7 | |
| UY36275A (en) | AMINOPIRIMIDINYL COMPOUNDS | |
| CY1122730T1 (en) | 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND THEIR USES | |
| BR112016028288A2 (en) | compound, pharmaceutical composition, methods for treating an individual with a disease or condition and for inhibiting kinase, and use of a compound. | |
| EA202091115A1 (en) | QUINAZOLINE DERIVATIVES USED FOR HIV TREATMENT | |
| MX379155B (en) | COMPOUNDS THAT INHIBIT THE MCL-1 PROTEIN. | |
| CR20160564A (en) | CYCLIC DINUCLEOTIDES AS STING MODULATORS | |
| EA201791304A1 (en) | IZOHINOLINA DERIVATIVES FOR HIV TREATMENT | |
| EA201891024A1 (en) | TANK-BINDING KINASE INHIBITOR COMPOUNDS | |
| MX380928B (en) | KRAS G12C INHIBITORS. | |
| MX377916B (en) | 4-AMINO-IMIDAZOQUINOLINE COMPOUNDS. | |
| MX382991B (en) | ARGININE METHYLTRANSFERASE INHIBITORS AND THEIR USES. | |
| MX376869B (en) | USEFUL METHODS IN THE SYNTHESIS OF HALICHONDRIN B ANALOGUES. | |
| MX376833B (en) | OXYSTEROLS AND METHODS OF USING THEM. | |
| EA201891063A1 (en) | DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER | |
| MX2017013797A (en) | Janus kinase inhibitor. | |
| MX382122B (en) | OXYSTEROLS AND METHODS OF USING THEM. | |
| DOP2016000253A (en) | NEW COMPOUNDS | |
| BR112015020139A2 (en) | therapeutic compounds and their uses | |
| EA201790627A1 (en) | STEMULATORS RHC | |
| EA201600434A1 (en) | APPLICATION OF DERIVATIVES OF BENZIMIDAZOLPROLINE | |
| AR094707A1 (en) | COMPOUND OF QUINAZOLIN-4-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE TREATMENT OF A DISEASE MEDIATED BY THE RIP2 KINASE | |
| EA201890532A1 (en) | NEW ANNELED BENZAMIDES | |
| CR20160016A (en) | SUBSTITUTED PIRAZOLPIRIDINS |